Business1 min read

STAT+: At ESMO, AstraZeneca’s cancer pursuits get a showcase

By · Via STAT Health · Published by Everything Blog

In short

AstraZeneca's cancer research was highlighted at ESMO, featuring 4 out of 12 presentations with AZ medicines, emphasizing the company's broad portfolio and quality data. The next targeted chemotherapy is expected to be showcased, indicating a promising future in oncology.

Key points

  • AstraZeneca's cancer initiatives were prominently featured at ESMO.: AstraZeneca's cancer initiatives were prominently featured at ESMO.
  • The company showcased its diverse portfolio and high-quality data.: The company showcased its diverse portfolio and high-quality data.
  • The next targeted chemotherapy is expected to be highlighted.: The next targeted chemotherapy is expected to be highlighted.

Sources checked by our analysis pipeline: 1

MADRID — For AstraZeneca, a major oncology conference here this weekend has been a sign of how the company’s cancer work is steamrolling ahead, with highlights from a mix of old standbys and new molecules that could expand its armament of medicines even further.

Four of the 12 presentations slotted in the presidential sessions at this year’s European Society for Medical Oncology’s congress featured AZ medicines. The meeting captured just how wide-ranging the company’s cancer work is, showing the power of new combinations of approved drugs and putting a spotlight on what could be the company’s next targeted chemotherapy to reach the market.

“That does speak to the breadth of the portfolio, but also the depth and quality of the data that we’re presenting,” Susan Galbraith, the head of AZ’s cancer R&D, told STAT.

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Original source: www.statnews.com

Business